RT @AshimaMakol: ðSuperb review of #SSc ILD by @sclerodermaUM #ACR21 ðEARLY/SUBCLINICAL is NOT Mild ILD ðMMF 1
Tweet Content
👌Superb review of #SSc ILD by @sclerodermaUM #ACR21
👉EARLY/SUBCLINICAL is NOT Mild ILD
👉MMF 1st
👉TCZ in combination for progressive phenotype/progression
👉Nintedanib:start slow, uptitrate for GI tolerability
👉Early HSCT referral (early dcSSc, FVC&DLCO 45-80%, Normal🫀) https://t.co/MUOhc3PakH
Show on Archive Page
On
Display in Search Results
On
PDQ
Off